Sutro Biopharma (STRO) Restructuring Costs (2025 - 2026)

Sutro Biopharma (STRO) posted Restructuring Costs of $1.6 million for Q4 2025, down 78.39% sequentially from $7.3 million in Q3 2025.

Sutro Biopharma (STRO) Restructuring Costs (2025 - 2026) Analysis & Trends

Sutro Biopharma has reported Restructuring Costs for 1 years, with the latest figure at $1.6 million in Q4 2025.

Quarterly Restructuring Costs changed N/A year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.1 million (changed N/A YoY) and the FY2025 annual result came in at $26.1 million, changed N/A from the prior year.
Restructuring Costs fell to $1.6 million in Q4 2025 per STRO's latest filing, from $7.3 million in the prior quarter.
Over five years, Restructuring Costs peaked at $13.0 million in Q2 2025 and troughed at $1.6 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Sutro Biopharma	339.58 Mn	175.24 Mn	-

Download Data